How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?
Cost of Care
Posted inCost of Care
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
Posted inCost of Care
The Aducanumab Aftermath: The Doctor
One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.
Posted inPublic Health
Babies, Boats & Abstracts: An Insider’s Guide to Health Policy Conferences
Health economist Kosali Simon shares conference tips, stories and abstracts she’s excited for at AcademyHealth and ASHEcon.
Posted inCost of Care
The FDA’s Pressure-Packed Alzheimer’s Drug Decision
The FDA weighs whether to approve a controversial new Alzheimer’s drug.
Posted inCost of Care
A Clearer Image of the Impact of Hospitals Buying Physician Practices
Ishani Ganguli on two new studies that use the number of imaging tests doctors order to understand the impact of hospitals buying physician practices.
Posted inCost of Care
Preventing HIV Just Got A Lot Cheaper. What Took So Long?
After nearly a decade of sky-high prices, new generics have sent the price of the HIV prevention drug PrEP plummeting.
Posted inInsurance
An ‘Automatic’ Solution to Keep People From Losing Health Coverage
Jose Figueroa on new research looking at the impact of a policy that automatically kept people insured even if they missed a payment.
Posted inCost of Care
How Much Free Care Do Hospitals Provide?
Vivian Ho on a new analysis looking at how much charity care different types of hospitals provide.
Posted inCost of Care
The Deadly Costs of Charging Patients More for Prescriptions
Adrianna McIntyre on research showing how increased cost-sharing leads to increased mortality.